文献速递临床试验与 GCP

阿柏西普、激光光凝或观察初始治疗对中心凹受累型糖尿病黄斑水肿且视力良好患者视力丧失的影响:一项随机临床试验

Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

该随机临床试验纳入702例1型或2型糖尿病成人患者,其研究眼为中心凹受累型糖尿病黄斑水肿且视力为20/25或更好,比较阿柏西普、局灶/格栅激光光凝或观察初始管理2年时视力丧失情况。结果显示三组至少5个字母视力下降比例无显著差异;仅视力恶化时再给阿柏西普的观察策略可能是合理策略。

要点

  • 中心凹受累型糖尿病黄斑水肿且视力20/25或更好者,2年时阿柏西普、激光光凝与观察三组至少5个字母视力下降比例无显著差异。
  • 激光光凝组25%(60/240)、观察组34%(80/236)因视力下降而启用阿柏西普。
  • 作者认为,除非视力恶化否则观察不治疗可能是中心凹受累型糖尿病黄斑水肿的合理策略。

核心结论

  • 中心凹受累型糖尿病黄斑水肿且视力良好者,初始采用阿柏西普或激光光凝或观察(仅视力恶化时给阿柏西普)管理,2年时视力丧失无显著差异。
  • 作者认为,除非视力恶化否则观察不治疗可能是中心凹受累型糖尿病黄斑水肿的合理策略。

研究设计与样本

  • 随机临床试验,在美国和加拿大91个中心开展,纳入702例1型或2型糖尿病成人患者。
  • 每例患者有1只研究眼为中心凹受累型糖尿病黄斑水肿且视力为20/25或更好。
  • 首例参与者于2013年11月8日随机分组,末次随访日期为2018年9月11日。

主要发现

  • 702例随机参与者平均年龄59岁,女性38%(n=264),625/681(92%,排除死亡)完成2年访视。
  • 2年时至少5个字母视力下降比例:阿柏西普组16%(33/205),激光光凝组17%(36/212),观察组19%(39/208)。
  • 阿柏西普 vs 激光光凝:风险差-2%(95%CI,-9%至5%),相对风险0.88(95%CI,0.57-1.35;P=.79)。
  • 阿柏西普 vs 观察:风险差-3%(95%CI,-11%至4%),相对风险0.83(95%CI,0.55-1.27;P=.79)。
  • 激光光凝 vs 观察:风险差-1%(95%CI,-9%至6%),相对风险0.95(95%CI,0.64-1.41;P=.79)。

关键数值与推荐

  • 视力较基线下降的眼,激光光凝组25%(60/240)和观察组34%(80/236)启用了阿柏西普。
  • 抗血小板试验协作组血管事件:阿柏西普组15例(7%),激光光凝组13例(5%),观察组8例(3%)。

临床怎么用

  • 作者认为,对于中心凹受累型糖尿病黄斑水肿且视力良好者,除非视力恶化否则观察不治疗可能是合理策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intravitreous injections of antivascular endothelial growth factor agents are effective for treating diabetic macular edema (DME) involving the center of the macula (center-involved DME [CI-DME]) with visual acuity impairment (20/32 or worse). The best approach to treating patients with CI-DME and good visual acuity (20/25 or better) is unknown. OBJECTIVE: To compare vision loss at 2 years among eyes initially managed with aflibercept, laser photocoagulation, or observation. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at 91 US and Canadian sites among 702 adults with type 1 or type 2 diabetes. Participants had 1 study eye with CI-DME and visual acuity of 20/25 or better. The first participant was randomized on November 8, 2013, and the final date of follow-up was September 11, 2018. INTERVENTIONS: Eyes were randomly assigned to 2.0 mg of intravitreous aflibercept (n = 226) as frequently as every 4 weeks, focal/grid laser photocoagulation (n = 240), or observation (n = 236). Aflibercept was required for eyes in the laser photocoagulation or observation groups that had decreased visual acuity from baseline by at least 10 letters (≥ 2 lines on an eye chart) at any visit or by 5 to 9 letters (1-2 lines) at 2 consecutive visits. MAIN OUTCOMES AND MEASURES: The primary outcome was at least a 5-letter visual acuity decrease from baseline at 2 years. Antiplatelet Trialists' Collaboration adverse events (defined as myocardial infarction, stroke, or vascular or unknown death) were reported. RESULTS: Among 702 randomized participants (mean age, 59 years; 38% female [n=264]), 625 of 681 (92% excluding deaths) completed the 2-year visit. For eyes with visual acuity that decreased from baseline, aflibercept was initiated in 25% (60/240) and 34% (80/236) in the laser photocoagulation and observation groups, respectively. At 2 years, the percentage of eyes with at least a 5-letter visual acuity decrease was 16% (33/205), 17% (36/212), and 19% (39/208) in the aflibercept, laser photocoagulation, and observation groups, respectively (aflibercept vs laser photocoagulation risk difference, -2% [95% CI, -9% to 5%]; relative risk, 0.88 [95% CI, 0.57-1.35; P = .79]; aflibercept vs observation risk difference, -3% [95% CI, -11% to 4%]; relative risk, 0.83 [95% CI, 0.55-1.27; P = .79]; laser photocoagulation vs observation risk difference, -1% [95% CI, -9% to 6%]; relative risk, 0.95 [95% CI, 0.64-1.41; P = .79]). Antiplatelet Trialists' Collaboration vascular events occurred in 15 (7%), 13 (5%), and 8 (3%) participants in the aflibercept, laser photocoagulation, and observation groups. CONCLUSIONS AND RELEVANCE: Among eyes with CI-DME and good visual acuity, there was no significant difference in vision loss at 2 years whether eyes were initially managed with aflibercept or with laser photocoagulation or observation and given aflibercept only if visual acuity worsened. Observation without treatment unless visual acuity worsens may be a reasonable strategy for CI-DME. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01909791.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Baker CW, Glassman AR, Beaulieu WT, et al. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. JAMA. 2019. PMID: 31037289. doi:10.1001/jama.2019.5790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。